|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Eli Lilly and Company |
| Information provided by: | Eli Lilly and Company |
| ClinicalTrials.gov Identifier: | NCT00065312 |
Purpose
The purpose of this study is to determine if an investigational drug is safe and efficacious for poorly controlled type 2 diabetes mellitus.
| Condition | Intervention | Phase |
|
Diabetes Mellitus, Non-Insulin-Dependent |
Drug: naveglitazar |
Phase II |
| MedlinePlus related topics: | Diabetes |
| Study Type: | Interventional |
| Study Design: | Treatment |
Eligibility
| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations![]() |
Show 42 Study Locations |
| Eli Lilly and Company |
More Information
| Study ID Numbers: | 5837, H7R-MC-GCBD |
| First Received: | July 21, 2003 |
| Last Updated: | July 18, 2006 |
| ClinicalTrials.gov Identifier: | NCT00065312 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|